Gabather reports positive preliminary fMRI results from the ongoing clinical study of GT-002

Wednesday 1 March 2023

Gabather AB (publ) (''Gabather'') reports positive preliminary fMRI data for the first four subjects in the ongoing clinical study of the drug candidate GT-002.  High-quality fMRI results show interesting differences in brain activity between the treatment groups, with particularly interesting results within the “Default Mode Network” (DMN), which monitors the flow of thought in the brain.

The study is a double-blind EEG/fMRI study with the aim to explore "target engagement”, which means studying the drug interaction with the GABA_A-receptor and which parts of the brain that are activated by the drug in question. The study, conducted at 2CA-Braga in Portugal, has generated high-quality fMRI data. The results come from the analysis of the blinded dataset from the first four subjects, out of a total of 24 healthy volunteers.

The results show interesting differences in brain activity in different brain areas between the treatment groups. Especially the “Default Mode Network" (DMN), that is a network of interacting brain regions that is active when a person is not focused on the outside world and the brain is at wakeful rest. DMN controls and monitors the flow of thought and decides what the brain should focus on.  It can be seen as the conductor of the brain. Disturbances in the DMN are linked to several common neuropsychiatric diagnoses, such as ADHD and depression.

The results will be included in the full analysis of the entire cohort. The final and complete analysis of the complete dataset will take place when all 24 healthy volunteers have received all treatments, which is expected to happen during the second quarter of 2023.

"This is very interesting and promising fMRI results that we have obtained for the first four subjects. The results indicate that GT-002 may have an impact on the mechanisms in the brain that cause great suffering for hundreds of thousands of people worldwide.  We are impressed by the results and look forward to the analysis of all 24 individuals” says Michael-Robin Witt, CEO of Gabather.

For more information, please contact:

Michael-Robin Witt, CEO

Phone: 073-687 28 39

E-mail: mrw@gabather.com

Briefly about Gabather AB

Based on pioneering research at Lund University and the Research Institute for Biological Psychiatry in Roskilde, Gabather was founded in 2014 with the aim of developing innovative and effective therapies for neuropsychiatric disorders. Our research and development focus on developing new pro-cognitive drug candidates targeting the GABA_A receptor for the treatment of disorders and imbalances in the central nervous system (CNS). GABA_A receptors are the main inhibitory signalling system in the brain that regulates central CNS functions. Dysfunction or imbalance in this system is known to be at the core of many neurological and neuropsychiatric disorders.

Certified Adviser is Erik Penser Bank, tel. 08- 463 80 00, e-mail: certifiedadvicer@penser.se